At a data monitoring committee's recommendation, Merck and Intercell have stopped clinical trials testing the efficacy of a potential staph infection vaccine, according to a BusinessWeek news report.
A data monitoring committee unanimously recommended halting the study of V710 after data showed the vaccine was not likely to have any significant benefits. Further, data showed patients treated with the vaccine were at increased risk of multiple organ failure and mortality (though the mortality risk was reportedly not statistically significant), according to the news report.
Read the news report about Merck and Intercell's V710.
Related Articles on Infections:
Report: Not All Teaching Hospitals Excel in Patient Safety
Physician Claims Milwaukee Hospital Prioritized Construction Over Infection Control
Study: Noisy ORs May Increase Risk of Surgical Site Infections
A data monitoring committee unanimously recommended halting the study of V710 after data showed the vaccine was not likely to have any significant benefits. Further, data showed patients treated with the vaccine were at increased risk of multiple organ failure and mortality (though the mortality risk was reportedly not statistically significant), according to the news report.
Read the news report about Merck and Intercell's V710.
Related Articles on Infections:
Report: Not All Teaching Hospitals Excel in Patient Safety
Physician Claims Milwaukee Hospital Prioritized Construction Over Infection Control
Study: Noisy ORs May Increase Risk of Surgical Site Infections